chronic hepatitis b virus epidemiology forecast insight

DelveInsight’s ‘Chronic Hepatitis B Virus (CHB) - Epidemiology Forecast to 2034’ report delivers an in-depth understanding of the disease, historical and forecasted CHB epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2034

Chronic Hepatitis B Virus (CHB) Understanding

Hepatitis B is the most common serious liver infection in the world. It is caused by the hepatitis B virus that attacks and injures the liver. Millions of people are living with a chronic hepatitis B infection all around the world. The hepatitis B virus (HBV) is transmitted through blood and infected bodily fluids. It can be passed to others through direct contact with blood, unprotected sex, and use of illegal drugs, unsterilized or contaminated needles. Children with hepatitis B are more likely to contract it through:

• Being born to a mother who has hepatitis B
• Living in the same house with someone who is infected with hepatitis B, and sharing items such as toothbrushes or razorblades
• Receiving multiple transfusions of blood or blood products
• Being bitten so that the skin is broken by someone whose saliva contains the hepatitis B virus
• Being a hemodialysis patient

HBV is most commonly spread through sexual contact, accounting for nearly two-thirds of acute HBV cases. It is considered as a “silent epidemic” because most people do not have symptoms when they are newly infected or chronically infected. Thus, they can unknowingly spread the virus to others and continue the silent spread of hepatitis B. Most hepatitis B infections clear up within 1–2 months without treatment. When the infection lasts more than 6 months, it can develop into chronic hepatitis B, which can lead to chronic inflammation of the liver, cirrhosis (scarring of the liver), liver cancer, and/or liver failure. HBV infection has been identified as an important cause of chronic hepatitis (35.9%) and liver cirrhosis (44.2%).

The symptoms of hepatitis B include fatigue, poor appetite, stomach pain, fever, nausea, vomiting, and occasionally joint pain, hives, or rash. Urine may become darker in color, and then jaundice (yellowing of the skin and whites of the eyes) may appear. Adults are more likely than children to develop symptoms; however, up to 50% of adults who have acute infection do not have any symptoms. The symptoms may appear within 6 weeks to 6 months after exposure, but usually 4 months. The virus can be found in blood and other body fluids several weeks before symptoms appear and generally persists for several months afterward.

Epidemiology Perspective by DelveInsight

The Chronic Hepatitis B Virus epidemiology division provides the insights about historical and current Chronic Hepatitis B Virus patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In 2020, the overall prevalent cases of CHB accessed to be around 5,858,038 in the 7MM, which are expected to grow during the forecast period, i.e., 2025-2034.

The disease epidemiology covered in the report provides historical as well as forecasted  Chronic Hepatitis B Virus epidemiology segmented as [Total Prevalent cases of CHB, Total Diagnosed Prevalent cases of  CHB, Gender-Specific Cases of CHB, Age-Specific Cases of CHB, CHB cases by Impact on Liver (i.e., decompensated and compensated), and Total treated cases of CHB] in the 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2034.

Country Wise- Chronic Hepatitis B Virus Epidemiology

Key Findings

• Among the 7MM, the United States accounted for nearly 40% of the total prevalent population of CHB in the year 2020.
• In EU-5 countries the highest number of diagnosed cases of CHB were in Germany, followed by Italy.
• As per the secondary findings, overall CHB Virus affects more males than females. In addition, around half of the CHB cases are reported in the people age group of 44 years and below. In the 7MM, the age-specific diagnosed prevalent cases of CHB were 60,561, 519,638, 479,929, 510,925, 366,771, and 93,968 cases for the age group less than 18 years, 18–34 years, 35–44 years, 45–54 years, 55–64 years, and ≥65 years, in 2020.

Scope of the Report

• The CHB report covers a detailed overview explaining its causes, symptoms, and pathophysiology, diagnosis, and treatment patterns.
• The CHB Report and Model provide an overview of the risk factors and global trends of CHB in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
• The report provides insight about the historical and forecasted patient pool of CHB in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of CHB.
• The report provides the segmentation of the CHB epidemiology by total prevalent cases in the 7MM.
• The report provides the segmentation of the CHB epidemiology by diagnosed prevalent cases in the 7MM.
• The report provides the segmentation of the CHB epidemiology by age-specific diagnosed prevalent cases in the 7MM.
• The report provides the segmentation of the CHB epidemiology by gender-specific diagnosed prevalent cases of CHB in the 7MM.
• The report provides the segmentation of the CHB epidemiology by Impact on Liver (i.e. decompensated and compensated) diagnosed prevalent cases of CHB in the 7MM.
• The report provides the segmentation of the CHB epidemiology by treated cases of CHB in the 7MM.

Report Highlights

• 10-Year Forecast of CHB epidemiology
• 7MM Coverage
• Epidemiology Segmentation

KOL-Views

We interview, KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over CHB scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to CHB?
• What are the key findings pertaining to the CHB epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017–2034)?
• What would be the total number of patients of CHB across the 7MM during the study period (2017–2034)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2034)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2017–2034)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of CHB ?

Reasons to buy

The CHB Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global CHB market
• Quantify patient populations in the global CHB market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for CHB therapeutics in each of the markets covered
• Understand the magnitude of CHB population by its severity
• The CHB epidemiology report and model were written and developed by Masters and PhD CHB  level epidemiologists
• The CHB Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 10-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population